Latest News

HHS effort aims to end new HIV cases within 10 years


 

FROM A HEALTH AND HUMAN SERVICES BRIEFING


George Sigounas, PhD, administrator or the Health Resources and Services Administration, said that existing community health centers will be especially important in reaching rural underserved and marginalized populations. Currently, he said, HRSA supports 12,000 service delivery sites across the country that are already delivering care to 27 million individuals. “These sites will play a major expanded role in providing PrEP to those who are at the greatest risk of contracting HIV,” said Dr. Sigounas.

Among the currently existing resources that will be leveraged are services provided by the Ryan White HIV/AIDS program, which already provides HIV primary medical care and support services through a network of grants to states and local government and community organizations. About half of the people currently diagnosed with HIV in the United States receive services through this program now.

The NIH maintains a geographically distributed network of Centers for AIDS Research that also will be folded into the new initiative.

In his remarks, Anthony S. Fauci, MD, director of the NIH’s National Center for Allergy and Infectious Diseases, pointed out that, “Treatment and detection are wrapped together, because treated individuals can’t transmit HIV” if they are adherent to antiretroviral medication use and achieve an undetectable viral load, he said. “If you get everyone who’s infected on antiretrovirals and give those who need it PrEP, you can theoretically end the epidemic as we know it – and that is our goal.”

Dr. Fauci went on to say that implementation science will play a key role in achieving a targeted and coordinated approach. “We will work closely with our colleagues to make sure the implementation is done well. We have lessons learned; we will do better and better,” he said.

The nuts and bolts of the program include a four-pronged strategy to diagnose individuals as early as possible after infection, to initiate prompt, effective, and sustained treatment, to protect those at risk for HIV by proven means including PrEP, and to provide rapid response when new HIV clusters are identified. A reimagining of current and future personnel into an “HIV health force” will put teams on the ground in each jurisdiction to carry out the initiative.

Though the goal is to provide PrEP to every at-risk individual, Dr. Fauci said that current modeling shows that if PrEP reaches 50%-60% in the at-risk population, new infections can be reduced by 90%. He added, “PrEP works. The efficacy is well over 90%.”

Funding details were not released at the press briefing; Dr. Giroir said that figures will be released by the Office of Management and Budget as part of the 2020 budget cycle. He confirmed, however, that new funds will be allocated for the effort, rather than a mere reshuffling of existing fund and resources.

Several of the leaders acknowledged the problem of stigma and marginalization that many individuals living with or at risk for HIV face, since men who have sex with men, transgender people, sex workers, and those with opioid use disorder all fall into this category.

“Every American deserves to be treated with respect and dignity. We will vigorously enforce all laws on the books about discrimination,” said Rear Adm. Michael Weahkee, MD, principal deputy director of the Indian Health Service. This is especially important in Native American communities “where everybody knows everybody,” he said, and it’s vitally important to include individual and community education in the efforts.

Dr. Redfield concurred, adding that “Dr. Fauci and I have been engaged in HIV since 1981. We have witnessed firsthand the negative impact that stigma can have on our capacity to practice public health. The transgender population, in particular, needs to be reached out to. We need to be able to address in a comprehensive way how to destigmatize the HIV population.”

Pages

Recommended Reading

Gene therapy moves from promise to reality
MDedge Hematology and Oncology
MDedge Daily News: Can androgen therapy improve male frailty?
MDedge Hematology and Oncology
HIV infection linked to higher risk of non-melanoma skin cancer
MDedge Hematology and Oncology
FDA approves epoetin alfa biosimilar to treat anemia
MDedge Hematology and Oncology
Hemophilia adherence tied to perception of disease
MDedge Hematology and Oncology
Blood pressure meds cut cognitive impairment risk
MDedge Hematology and Oncology
HIV-associated Kaposi sarcoma responds to checkpoint inhibitors
MDedge Hematology and Oncology
Virus-specific T-cell infusion may resolve progressive multifocal leukoencephalopathy
MDedge Hematology and Oncology
Checkpoint inhibitor seems safe and effective for patients with HIV
MDedge Hematology and Oncology
HBV, HCV, HIV testing of new cancer patients advised
MDedge Hematology and Oncology